From theheart.org on Medscape

Coverage from the

European Society of Cardiology (ESC) Congress 2019, World Congress of Cardiology

August 31 - September 04, 2019; Paris, France

August 31 - September 04, 2019 Paris, France

Conference News

© WebMD, LLC

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Perspectives

 

Bloggers from the Floor

  • Will DAPA-HF Turn the Tide on Heart Failure? The term gamechanger is overused but may be appropriate for the DAPA-HF trial on the SGLT2 inhibitor dapagliflozin in patients with heart failure and reduced ejection fraction. Medical conservative John Mandrola, MD, was impressed.
  • When Guideline Authors Dismiss Important Studies Why does a guideline document on chronic coronary disease exclude the landmark ORBITA trial? Perhaps it's an existential tension, suggests John Mandrola, MD.
  • PARAGON-HF: Heart Failure With Preserved EF Proves a Tough Foe Given the few effective therapies for HFpEF, should a new expensive drug be adopted on the basis of a borderline clinical trial result? John Mandrola, MD, weighs in.
  • Mandrola Previews ESC 2019 Read what John Mandrola, MD, is looking forward to in Paris. Despite some advance spoilers, there will be plenty to pique the interest of the average cardiologist.
 
 

Popular News from ESC 2018

Previous Coverage